`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MEDIVIS, INC.,
`Petitioner,
`
`v.
`
`NOVARAD CORP.,
`Patent Owner.
`
`
`
`IPR2023-00042 (Patent 11,004,271 B2)
`
`
`
`
`
`
`OBJECTIONS TO PETITIONER’S EVIDENCE
`PURSUANT TO 37 C.F.R. § 42.64(b)(1)
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.64(b)(1) and the Federal Rules of Evidence,
`
`patent owner Novarad Corp. (“Patent Owner”) hereby objects to the evidence of
`
`petitioner Medivis, Inc. (“Petitioner”) proffered in connection its Petition for Inter
`
`Partes Review filed on October 12, 2022, for the reasons set forth below.
`
`
`
`IPR2023-00042 (Patent 11,004,271 B2)
`
`
`I.
`
`Patent Owner Objects to Exhibits 1005, 1007, 1010, and 1014
`
`Ex. 1005
`
`FRE 106 (Incomplete); FRE 402, 403, 703 (Irrelevant); FRE 802
`(Hearsay)
`
`Ex. 1007
`
`FRE 802 (Hearsay); FRE 402, 403, 703 (Irrelevant)
`
`Ex. 1010
`
`FRE 802 (Hearsay); FRE 402, 403, 703 (Irrelevant)
`
`Ex. 1014
`
`FRE 402, 403, 703 (Irrelevant)
`
`
`
`Ex. 1005 (“Amira”)
`
`FRE 402, 403, 703. Ex 1005 is purportedly the first two chapters (Chapter 1:
`
`Introduction and Chapter 2: First steps in Amira) of a user guide for computer
`
`software (Amira 5) used to visualize, analyze, and model three-dimensional data
`
`on a two-dimensional computer monitor. Petitioner has not established the
`
`authenticity of Ex. 1005 or whether it was disseminated or otherwise made
`
`accessible to persons interested and ordinarily skilled in the subject to which Ex.
`
`1005 relates prior to the critical date. Thus, Ex. 1005 has no tendency to make a
`
`fact more or less probable that it would be without use of the evidence. Also, it is
`
`of no consequence in determining the outcome of the proceeding.
`
`
`
`IPR2023-00042 (Patent 11,004,271 B2)
`
`
`FRE 802. Ex. 1005 is an out-of-court statement offered to prove the truth of the
`
`matter asserted in statements by Dr. Kazanzides. Moreover, no hearsay exceptions
`
`apply, including Fed. R. Evid. 803(18), because neither Dr. Kazanzides or any
`
`other expert has established that Ex. 1005 comes from a reliable authority.
`
`FRE 106. Exhibit 1005 purports to be an “Excerpt of Amira 5 User’s Guide title
`
`through Chapter 2.” Under Fed. R. Evid. 106, in fairness, Patent Owner requires
`
`Petitioner to produce the complete Amira 5 User Guide.
`
`Ex. 1007 (“3D Visualization”)
`
`FRE 402, 403, 703. Ex 1007 is purportedly a slide deck from a presentation given
`
`at “Surgical Planning Laboratory, Brigham and Women’s Hospital in Boston,
`
`Massachusetts.” The document does not indicate when this presentation was
`
`given. The presentation allegedly provides an introduction to “the 3DSlicer
`
`software.” Ex. 1007 at 3. Users allegedly use the 3DSlicer software to visualize,
`
`analyze, and model three-dimensional data on a two-dimensional computer
`
`monitor. Petitioner has not established the authenticity of Ex. 1007 or whether it
`
`was disseminated or otherwise made accessible to persons interested and ordinarily
`
`skilled in the subject to which Ex. 1007 relates prior to the critical date. Thus,
`
`Ex. 1007 has no tendency to make a fact more or less probable that it would be
`
`
`
`without use of the evidence. Also, it is of no consequence in determining the
`
`IPR2023-00042 (Patent 11,004,271 B2)
`
`
`outcome of the proceeding.
`
`FRE 802. Ex. 1007 is an out-of-court statement offered to prove the truth of the
`
`matter asserted in statements by Dr. Kazanzides. Moreover, no hearsay exceptions
`
`apply, including Fed. R. Evid. 803(18), because neither Dr. Kazanzides or any
`
`other expert has established that Ex. 1007 comes from a reliable authority.
`
`Ex. 1010 (“3D Slicer”)
`
`FRE 402, 403, 703. Ex 1010 is purportedly online documentation for the 3DSlicer
`
`software. Again, users allegedly use the 3DSlicer software to visualize, analyze,
`
`and model three-dimensional data on a two-dimensional computer monitor.
`
`Petitioner has not established the authenticity of Ex. 1010 or whether it was
`
`disseminated or otherwise made accessible to persons interested and ordinarily
`
`skilled in the subject to which Ex. 1010 relates prior to the critical date. Thus, Ex.
`
`1010 has no tendency to make a fact more or less probable that it would be without
`
`use of the evidence. Also, it is of no consequence in determining the outcome of
`
`the proceeding.
`
`FRE 802. Ex. 1010 is an out-of-court statement offered to prove the truth of the
`
`matter asserted in statements by Dr. Kazanzides. Moreover, no hearsay exceptions
`
`
`
`IPR2023-00042 (Patent 11,004,271 B2)
`
`
`apply, including Fed. R. Evid. 803(18), because neither Dr. Kazanzides or any
`
`other expert has established that Ex. 1010 comes from a reliable authority.
`
`Ex. 1014 (“Novarad Litigation Counsel Email”)
`
`FRE 402, 403, 703. Ex. 1014 is an email message dated August 3, 2022, between
`
`Novarad’s and Medivis’ litigation counsel concerning “claim construction issue
`
`identification” in the Scheduling Order in the related civil lawsuit pending in the
`
`U.S. District Court for the District of Delaware (21-1447-GBW) and is wholly
`
`irrelevant to this proceeding. Moreover, in its Petition, Petitioner acknowledged,
`
`“Claim construction [in the related litigation] has not been briefed or argued. In
`
`short, the case remains in its earliest stages.” ’271 Petition at 2-3.
`
`II.
`
`Patent Owner’s Objects to Ex. 1012—Dr. Kazanzides’ Declaration
`
`Patent Owner objects to Exhibit 1012, Dr. Kazanzides’ Declaration for the
`
`following reasons:
`
`FRE 703 (Relies on
`inadmissible evidence.)
`
`Ex. 1005
`
`¶¶ 49, 82-88, 90-100.
`
`Ex. 1007
`
`¶¶ 106, 118, 121, 126, 128, 131
`
`Ex. 1010
`
`¶¶ 106, 120, 126
`
`Ex. 1014
`
`¶ 28.
`
`
`
`FRE 702, 703 (Conclusory.
`Insufficient Facts or
`Information.)
`
`FRE 704 (Improper legal
`conclusion.)
`
`FRE 402, 403 (Irrelevant)
`
`IPR2023-00042 (Patent 11,004,271 B2)
`
`
`¶ 64, 68, 73, 77-79, 83, 84, 96, 101, 103, 106,
`110, 112, 117, 127, 129-130, 132.
`
`¶¶ 59-60, 62, 81, 108.
`
`
`
`Ex. 1012 is irrelevant and unfairly prejudicial to
`the extent it: (1) relies of inadmissible evidence;
`(2) is conclusory or fails to rely on sufficient
`facts or information; or (3) states an improper
`legal conclusion.
`
`
`
`
`
`
`
`Date: May 8, 2023
`
`Respectfully submitted,
`
`
`
`By: /s/ Jed Hansen
`
`Jed Hansen, Reg. No. 59,106
`Joseph Harmer, Reg. No. 77,649
`Attorneys for Patent Owner
`
`
`
`
`
`IPR2023-00042 (Patent 11,004,271 B2)
`
`
`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that a correct copy of the OBJECTIONS
`TO PETITIONER’S EVIDENCE PURSUANT TO 37 C.F.R. § 42.64(b)(1) were
`served electronically upon the Petitioner on May 8, 2023, to the email addresses
`identified in Petitioner’s Updated Mandatory Notices dated February 2, 2023:
`
`
`kfreeman@mccarter.com
`ebelt@mccarter.com
`jcurran@mccarter.com
`
`
`Date: May 8, 2023
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Kaelynn Moultrie
`Kaelynn Moultrie
`
`